Emerging agents and regimens for multiple myeloma

Journal of Hematology & Oncology

Yang Yang¹  Huiyao Gu¹  Yi Li¹  Mengmeng Dong¹  Zhen Cai² 

[1] Bone Marrow Transplantation Center, Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China;Bone Marrow Transplantation Center, Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China;Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, China;Zhejiang Laboratory for Systems and Precision Medicine, Zhejiang University Medical Center, Hangzhou, Zhejiang, China;

关键词: Multiple myeloma;    Monoclonal antibody;    Immunotherapy;    Checkpoint inhibitor;    BiTE;    CAR-T;   

DOI  :  10.1186/s13045-020-00980-5

来源: Springer

【 摘 要 】

The outcomes of multiple myeloma (MM) have been improved significantly with the therapies incorporating proteasome inhibitors (PI), immunomodulatory drugs, monoclonal antibodies (MoAb) and stem cell transplantation. However, relapsed and refractory MM (RRMM) remains a major challenge. Novel agents and regimens are under active clinical development. These include new PIs such as ixazomib, marizomib, and oprozomib; new MoAbs such as isatuximab and MOR202; novel epigenetic agent ricolinostat and novel cytokines such as siltuximab. Recently, the first XPO-1 inhibitor, selinexor, was approved for RRMM. BCMA-targeted BiTE, antibody–drug conjugates and CAR-T cells have the potential to revolutionize the therapy for RRMM. In this review, we summarized the latest clinical development of these novel agents and regimens.

【 授权许可】

CC BY